Skip to content
Emami logo

Emami

EMAMILTD NSE
₹422.20 −2.90 (−0.68%)
Market Cap
₹18,429 Cr
P/E
24.76
View as Markdown
MCP
Close 20 Nov 2026 ₹422.20 1Y −84.60 −16.7%
Start ₹506.80

Key Fundamentals

SmallcapPersonal ProductsFMCG

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
28.10%
Debt to Equity
0.08
EPS (TTM)
₹17.05
Book Value
₹67.03
Market Cap
₹18,429 Cr
P/E (TTM)
24.76
P/B
6.30
ROE
26.20%
Dividend Yield
1.18%
EBITDA
₹1,049 Cr
52W High
₹550.90
52W Low
₹357.00
Day Range
₹419.50 – ₹425.00
Volume
3,09,278

Peer Comparison

Fast Moving Consumer Goods › Personal Products › Personal Care

Emami peer comparison
919.5047.5794,0937.461.67%16.10%18.80%16,5371,978
393.1034.4269,7346.070.92%17.00%20.30%13,9242,001
365.65290.2049,16887.481.38%27.60%33.90%602169
1,760.0035.1547,86929.601.42%82.70%108.00%6,3911,362
7,090.5033.8023,10521.513.31%66.50%90.70%3,211683
7,020.0029.3422,78725.783.73%115.00%157.00%4,240776
Emami (this company)
422.2024.7618,4296.301.21%26.20%28.10%4,204747
Median 7 companies919.5034.4247,86921.511.42%27.60%33.90%4,240776

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

60 Good

Data confidence 100/100

Category scores

Quality
82
Strong
Returns, margins, earnings quality 22% weight
Valuation
45
Average
Cheap vs sector & own history 24% weight
Growth
57
Good
Sales & profit trajectory 9% weight
Financial Health
90
Strong
Solvency, leverage, coverage 9% weight
Momentum
65
Good
Trend strength, vol-adjusted 12% weight
Ownership
48
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.5%
  • Company has been maintaining a healthy dividend payout of 52.9%
  • Debtor days have improved from 42.3 to 33.2 days.

Weaknesses

1
  • The company has delivered a poor sales growth of 5.58% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish6112
OscillatorsStrong Bearish513
Moving AveragesStrong Bullish109

Key readings

RSI (14)
70.10
Bearish
MACD (12,26,9)
11.58
Bullish
SMA (50)
383.33
Bullish
SMA (200)
413.75
Bullish

As of

Analyst Rating

Based on 22 analysts
BUY86%

19 of 22 analysts rate Buy, 3 Hold, 0 Sell.

As of

BUY
19
86%
HOLD
3
14%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+4.83%
5Y+5.58%
3Y+3.53%
1Y−0.76%
TTM+13.16%

Net profit

Net profit growth by window
10Y+7.88%
5Y+11.24%
3Y+7.32%
1Y−3.49%
TTM−0.80%

Operating cash flow

Operating cash flow growth by window
10Y+3.61%
5Y−2.77%
3Y+2.26%
1Y−10.60%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−3.78 pp
5Y−5.14 pp
3Y+0.30 pp
1Y−1.22 pp
TTM−1.17 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,488 Cr
Mar 2018₹2,531 Cr
Mar 2019₹2,695 Cr
Mar 2020₹2,655 Cr
Mar 2021₹2,881 Cr
Mar 2022₹3,192 Cr
Mar 2023₹3,406 Cr
Mar 2024₹3,578 Cr
Mar 2025₹3,809 Cr
Mar 2026₹3,780 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹340 Cr
Mar 2018₹306 Cr
Mar 2019₹303 Cr
Mar 2020₹302 Cr
Mar 2021₹455 Cr
Mar 2022₹837 Cr
Mar 2023₹627 Cr
Mar 2024₹724 Cr
Mar 2025₹803 Cr
Mar 2026₹775 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹411 Cr +68.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk medium

Emami Ltd trades at ₹412.6 as of 2026-11-17 with a market cap of ₹18,010 Cr, a PE of 24.2x, and a near-debt-free balance sheet (debt-to-equity of 0.06). The company demonstrates strong return ratios with a 5-year average ROE of 31% but faces headwinds from sluggish long-term sales and profit growth alongside a stock price that has declined 21% over the past year.

Bull Case 7
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.06, providing significant financial flexibility and resilience against interest rate cycles.
  • Excellent return on equity track record with a 5-year average ROE of 31% and a 3-year average of 28%, well above most FMCG peers, indicating efficient capital allocation.
  • ROCE stands at 28.59% as of 2026-11-17, reflecting strong operating profitability and efficient use of total capital employed.
  • Healthy dividend payout ratio of 52.9% with a current dividend yield of 1.21%, rewarding shareholders consistently while retaining enough for growth.
  • TTM sales growth has accelerated to 13%, a notable improvement over the 3-year compounded sales growth of 4% and 5-year CAGR of 6%, suggesting a possible revenue inflection.
  • Improvement in working capital efficiency with debtor days declining from 42.3 to 33.2 days, indicating better cash conversion and receivables management.
  • 10-year ROE has been sustained at 26%, demonstrating long-term consistency in generating shareholder returns across business cycles.
Bear Case 6
  • Stock has delivered negative returns across all measured horizons — 1-year CAGR of -21%, 3-year CAGR of -6%, 5-year CAGR of -4%, and 10-year CAGR of -3% — indicating persistent value erosion for shareholders.
  • Compounded sales growth has been tepid at just 5% over 10 years and 4% over 3 years, reflecting limited ability to scale revenues meaningfully in a competitive FMCG landscape.
  • TTM profit growth is flat at 0% despite TTM sales growing 13%, suggesting margin compression or rising costs that are eating into bottom-line expansion.
  • Compounded profit growth of only 5% over 3 years and 6% over 10 years lags behind broader FMCG sector growth rates, raising questions about long-term earnings scalability.
  • PE of 24.2x on an EPS of ₹17.05 demands sustained earnings acceleration to justify the valuation, yet the 5-year compounded profit growth of 11% has moderated to 0% on a TTM basis.
  • The stock sits only 15.6% above its 52-week low of ₹357, and is down substantially from its 52-week high of ₹550.9, reflecting weak market sentiment and potential further downside risk.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

21h ago

TL;DR: Emami is showing strong topline momentum with high-double digit October sales growth and guided 18-20% core H2 growth. Promoter pledge levels are trending down, a modest positive for sentiment. Key risks include higher-than-guided strategic investments and persistent input cost pressure delaying margin expansion. The operational trend is improving, but margin recovery remains a next-year story.

Headwinds 2
  • Strategic investment overshoot Nov 6

    Strategic investment run rate at ₹1,000-1,100 crore versus earlier guidance of ₹800-850 crore, indicating higher-than-expected spending that could weigh on near-term profitability.

  • High input cost pressure Nov 6

    Gross margins improvement is projected only for next year, implying current elevated input costs continue to compress margins in the near term.

Positives 2
  • Strong October sales momentum Nov 6

    October sales reported high-double digit growth. Core business expected to grow 18-20% in H2FY27, signaling robust demand recovery.

  • Promoter releases pledged shares Nov 14

    Diwakar Finvest and Suraj Finvest released pledged Emami shares to DCB Bank, HSBC, and IDBI. Diwakar's encumbered holding now stands at 5.43% of total share capital, reflecting improving promoter financial health.

Neutral 2
  • Promoter pledge adjustments Oct 30

    Diwakar Finvest released 41 lakh shares while Suraj Finvest pledged 21.4 lakh shares in late October 2026, resulting in a net release of roughly 19.6 lakh shares.

  • KMP disclosure list updated Nov 5

    Emami disclosed authorized Key Managerial Personnel for materiality determination and disclosures under SEBI Listing Regulations, effective November 5, 2026.

Quarterly Results

₹ Cr
EMAMILTD quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
865
996
891
906
891
1,049
963
904
799
1,152
925
1,039
1,088
Expenses
632
682
682
692
645
715
744
692
622
768
739
815
866
Operating Profit
233
314
209
214
246
334
219
212
177
384
186
225
222
OPM %
27%
32%
24%
24%
28%
32%
23%
23%
22%
33%
20%
22%
20%
Other Income
11
11
11
10
22
15
21
22
21
18.97
23
18
23
Interest
2
3
3
2
2
2
3
2
3
3
3
6
6
Depreciation
46
46
48
44
45
46
44
44
45
45
42
43
45
Exceptional Items
—
—
—
—
—
—
—
—
—
−10.15
—
—
—
PBT
196
276
169
178
220
301
194
187
150
345
164
195
194
Tax %
8%
6%
13%
16%
4%
7%
16%
12%
1%
7%
13%
29%
25%
Net Profit
180
261
147
151
211
279
162
164
148
319
143
139
146
EPS (₹)
4.09
5.92
3.41
3.50
4.87
6.39
3.72
3.76
3.40
7.32
3.28
3.15
3.30
YoY Sales growth
6
1
7
10
3
5
8
0
−10
10
−4
15
36

Profit & Loss

₹ Cr
EMAMILTD profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,076
2,358
2,488
2,531
2,695
2,655
2,881
3,192
3,406
3,578
3,809
3,780
4,204
Expenses
1,536
1,670
1,729
1,812
1,970
1,970
2,000
2,254
2,550
2,632
2,796
2,820
3,187
Operating Profit
541
688
759
719
725
685
880
938
855
946
1,014
960
1,017
OPM %
26%
29%
31%
28%
27%
26%
31%
29%
25%
26%
27%
25%
24%
Other Income
91
44
31
19
25
46
69
90
69
41
68
85.11
74
Interest
5
54
58
34
21
21
13
5
7
10
9
11
18
Depreciation
34
255
309
311
325
336
367
335
247
186
178
177
176
Exceptional Items
—
—
—
—
—
—
—
—
—
—
—
−10.15
—
PBT
592
423
424
393
403
374
569
688
670
791
894
846
897
Tax %
18%
14%
20%
22%
25%
19%
20%
−22%
6%
8%
10%
8%
—
Net Profit
485
363
340
306
303
302
455
837
627
724
803
775
747
EPS (₹)
10.70
8.00
7.50
6.77
6.68
6.67
10.23
19.02
14.50
16.58
18.48
17.76
17.05
Div. Payout %
33%
44%
47%
52%
60%
60%
78%
42%
55%
48%
54%
56%
—
Sales growth
22
14
6
2
6
−1
8
11
7
5
6
−1
13

Balance Sheet

₹ Cr
EMAMILTD balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
23
23
23
23
45
45
44
44
44
44
44
44
44
Reserves
1,208
1,589
1,732
1,991
2,031
1,778
1,718
2,032
2,259
2,403
2,651
2,880
2,882
Borrowings
36
671
473
326
110
210
101
282
91
94
90
162
231
Other Liabilities
410
409
376
458
633
644
656
692
703
728
741
745
1,329
Total Liabilities
1,676
2,692
2,603
2,798
2,819
2,678
2,520
3,050
3,096
3,269
3,525
3,831
4,485
Fixed Assets
453
1,918
1,994
1,802
1,680
1,459
1,132
1,344
1,245
1,114
984
886
1,684
CWIP
29
67
22
30
36
8
6
3
6
8
15
1
2
Investments
501
104
128
314
187
156
255
303
293
442
676
834
502
Other Assets
693
604
460
652
915
1,055
1,126
1,400
1,551
1,706
1,850
2,108
2,297
Total Assets
1,676
2,692
2,603
2,798
2,819
2,678
2,520
3,050
3,096
3,269
3,525
3,831
4,485

Cash Flow

₹ Cr
EMAMILTD cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
534
562
730
588
554
531
922
644
749
779
896
801
Investing
−237
−1,313
−306
−276
−26
−231
−224
−234
−122
−210
−345
−174
Financing
−215
502
−496
−324
−428
−405
−688
−402
−608
−563
−500
−554
Net Cash Flow
82
−249
−72
−12
100
−106
9
8
19
6
52
72
Free Cash Flow
426
430
448
465
421
383
890
164
719
750
852
770
CFO/EBITDA
116
96
105
93
89
89
115
84
101
98
107
101

Ratios

EMAMILTD financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
18
20
14
22
29
42
29
37
44
50
43
33
Inventory Days
59
68
83
87
88
102
118
121
100
102
94
128
Days Payable
90
112
85
109
115
135
138
138
124
143
133
153
Cash Conversion Cycle
−13
−24
12
1
2
9
10
19
20
9
4
8
Working Capital Days
−16
−54
−62
−32
−6
7
−3
0
28
30
25
21
ROCE %
61%
30%
23%
22%
19%
18%
29%
31%
28%
32%
32%
28%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Emami insights

78 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 54.84%
  • DIIs 23.58%
  • FIIs 9.02%
  • Others 6.32%
  • Public 6.24%

15.06% of promoter holding pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Emami

What does Emami Ltd do?
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.
Where is Emami Ltd (EMAMILTD) listed?
Emami Ltd trades as EMAMILTD on the NSE and under code 531162 on the BSE.
Which sector does Emami Ltd belong to?
Emami Ltd is classified under the Fast Moving Consumer Goods sector, in the Personal Products industry.
What is the market capitalisation of Emami Ltd?
Emami Ltd has a market capitalisation of ₹18,429 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Emami Ltd?
Emami Ltd trades at a PE ratio of 24.76 as of 20 Nov 2026, on earnings per share of ₹17.05, against a book value of ₹67.03 per share.
What is the 52-week high and low of Emami Ltd?
Over the last 52 weeks Emami Ltd has traded between ₹357 and ₹550.9 as of 20 Nov 2026.
Does Emami Ltd pay dividends?
Emami Ltd has a dividend yield of 1.18%.
What is the Return on Equity (ROE) of Emami Ltd?
Emami Ltd reported a return on equity of 26.20%. Its debt-to-equity ratio is 0.08.

Company Information

Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.

Website emamiltd.in
CEO Mr. Radhe Shyam Goenka B.Com., L.L.B., M.Com. LLB
Employees 3,217
Listed 3 Aug 2006
Face Value ₹1
Shares Outstanding 43,65,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/EMAMILTD.md for Emami Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More